Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer

3 de dezembro de 2017 atualizado por: Masonic Cancer Center, University of Minnesota

MT2008-15: Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematological Malignancies Using a Nonmyeloablative Preparative Regimen and Priming With Complement 3a Fragment (C3a)

RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect).

PURPOSE: This phase I trial is studying the safety of donor umbilical cord blood transplant after fludarabine phosphate, cyclophosphamide, and total-body irradiation in treating patients with high-risk hematologic cancer (now closed).

The Phase II part of this trial is studying whether priming one of two UCB units with C3a facilitates engraftment of the treated unit.

Visão geral do estudo

Descrição detalhada

OUTLINE:

  • Nonmyeloablative preparative regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on day -6. Patients then undergo total-body irradiation on day -1. Some patients also receive anti-thymocyte globulin IV every 12 hours on days -6, -5, and -4.
  • Umbilical cord blood (UCB) transplantation: Patients undergo unmanipulated UCB transplantation followed by complement 3a fragment primed UCB transplantation on day 0.

Treatment for graft-vs-host disease prophylaxis is also given.

After completion of study therapy, patients are followed up periodically for up to 2 years.

Tipo de estudo

Intervencional

Inscrição (Real)

31

Estágio

  • Fase 2
  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Minnesota
      • Minneapolis, Minnesota, Estados Unidos, 55455
        • University of Minnesota Medical Center - Fairview

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 75 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Disease Criteria

    • Acute Leukemias: Must be in remission by morphology (<5% blasts). Note cytogenetic relapse or persistent disease without morphologic relapse is acceptable. Also a small percentage of blasts that is equivocal between marrow regeneration vs. early relapse are acceptable provided there are no associated cytogenetic markers consistent with relapse. (See exclusion criteria for more detailed definition)
    • Acute myeloid leukemia: high risk CR1 (as evidenced by preceding myelodysplastic syndrome (MDS), high risk cytogenetics such as those associated with MDS or complex karyotype, > 2 cycles to obtain complete remission (CR) or erythroblastic and megakaryocytic); second or greater CR.
    • Acute lymphoblastic leukemia/lymphoma: high risk CR1 as evidenced by high risk cytogenetics (e.g. t(9;22, t(1;19), t(4;11), other MLL rearrangements) or > 1 cycle to obtain CR; second or greater CR.
    • Burkitt's lymphoma in CR2 or subsequent CR
    • Natural Killer cell malignancies
    • Myeloproliferative syndromes/diseases: Chronic myelogenous leukemia (CML) in chronic or accelerated phase but patients must have failed or been intolerant to Imatinib mesylate. EXCLUDED: CML in refractory blast crisis, myelofibrosis, polycythemia vera, and essential thrombocytosis.
    • Myelodysplastic Syndrome: any subtype including refractory anemia (RA) if severe pancytopenia, high risk complex cytogenetics or International Prognostic Scoring System (IPSS) ≥ intermediate-2 (Int-2). Blasts must be less than 5%. If 5% or more requires therapy pre-transplant to reduce blast count to ≤5%. Patients who receive single agent 5-azacytidine, decitabine or immunomodulating drugs are eligible.
    • Large-cell lymphoma, Hodgkin's lymphoma and multiple myeloma: patients with chemotherapy sensitive disease that has failed or who are ineligible for an autologous transplant. Patients are eligible for umbilical cord blood (UCB) transplantation if there is no evidence of progressive disease by imaging modalities and/or biopsy. Persistent PET activity, though possibly related to lymphoma, IS NOT an exclusion criterion in the absence of computated tomography (CT) changes in size indicating progression. Large-cell and Hodgkin's lymphoma that is progressive on salvage therapy is NOT eligible. Patients with stable disease are eligible for transplantation if the largest residual nodal mass is < 5 cm (approximately). For patients who have responded to preceding therapy, the largest residual mass must represent a 50% reduction and be < 7.5 cm (approximately).
    • Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone B-cell lymphoma, follicular lymphoma which have progressed after at least two prior therapies. Patients with bulky disease should be considered for debulking chemotherapy before transplant. Patients with refractory disease are eligible, unless has bulky disease and an estimated tumor doubling time of less than one month. Patients with stable disease are eligible for transplantation if the largest residual nodal mass is < 5 cm (approximately). For patients who have responded to preceding therapy, the largest residual mass must represent a 50% reduction and be < 7.5 cm (approximately).
    • Lymphoplasmacytic lymphoma, mantle-cell lymphoma, prolymphocytic leukemia are eligible after initial therapy if chemotherapy sensitive. Mantle-cell lymphoma that is progressive on salvage therapy is NOT eligible. Patients with stable disease are eligible for transplantation if the largest residual nodal mass is < 5 cm (approximately). For patients who have responded to preceding therapy, the largest residual mass must represent a 50% reduction and be < 7.5 cm (approximately).
  • Umbilical Cord Blood Graft Selection - Two UCB units will be compose the graft, and each unit must be a 4-6 HLA-A, B, DRB1 antigen match to each other, as well as a 4-6 antigen match to the recipient. The combined cryopreserved nucleated cell dose of the 2 units must be ≥ 3 X 10^7/kg with each unit having a minimum cell dose of 1.5 X 10^7/kg. UCB units will be selected according to a common umbilical cord blood graft selection algorithm
  • Performance Status - adequate performance status defined as Karnofsky score ≥ 60
  • Age 18 to 70 years of age; patients ≥ 70 but ≤ 75 years are eligible if the co-morbidity score is ≤ 2
  • Organ Function

    • Cardiac: Left ventricular ejection fraction > 35%; absence of decompensated congestive heart failure; absence of uncontrolled arrhythmia
    • Pulmonary: DLCO > 30% of predicted; absence of O2 requirements
    • Hepatic: ALT, AST, alkaline phosphatase and bilirubin < 5 x upper limit of normal
    • Renal: Creatinine ≤ 2 mg/dl (patients with a creatinine > 1.2 or history of renal dysfunction must have calculated glomerular filtration rate (GFR) > 40 mL/min/1.73m2)
    • If recent mold infection e.g. Aspergillus - must have minimum of 30 days of appropriate treatment before transplant and infection controlled and be cleared by Infectious Disease.
    • The following conditions must be met:

      • If prior myeloablative autologous transplant, must be > 3 months but ≤ 12 months from transplant OR have received at least 2 cycles of multi-agent or highly immunosuppressive chemotherapy (i.e. induction for acute leukemia) within the 3 months preceding this study. OR
      • If neither prior myeloablative autologous transplant ≤ 12 months from transplant nor have received at least 2 cycles of multi-agent or highly immunosuppressive chemotherapy (i.e. induction for acute leukemia) within the 3 months preceding this study, patients are eligible as long as they receive equine anti-thymocyte globulin as part of the conditioning regimen.

Exclusion Criteria:

  • Patients who have an available, medically suitable, 5-6/6 HLA-A, B, DRB1 matched sibling donor
  • Patients who are eligible for autologous transplantation
  • Prior allogeneic transplant
  • Acquired or inherited bone marrow failure syndromes such as aplastic anemia and Fanconi anemia
  • Pregnant or breast feeding
  • Evidence of HIV infection or known HIV positive serology
  • Current uncontrolled serious infection
  • Active central nervous system malignancy

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Complement Fragment 3A - Small Cell Dose
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
200 cGy no Dia -1
50 mg/kg intravenously (IV) over 2 hours on Day -6.
Outros nomes:
  • Cytoxan
40 mg/m^2 over 1 hour on Days -6 through -2.
Outros nomes:
  • Fludara
On Day 0, the C3a primed UCB unit will be infused intravenously SECOND, within 30 minutes of the completion of the infusion of the unmanipulated UCB unit, through a central line without in-line filtration in a manner identical to the unmanipulated UCB unit.
On Day 0, the unmanipulated UCB unit will be infused FIRST through a central line without in-line filtration per institutional guidelines.
Experimental: Complement Fragment A - Larger Cell Dose
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
200 cGy no Dia -1
50 mg/kg intravenously (IV) over 2 hours on Day -6.
Outros nomes:
  • Cytoxan
40 mg/m^2 over 1 hour on Days -6 through -2.
Outros nomes:
  • Fludara
On Day 0, the C3a primed UCB unit will be infused intravenously SECOND, within 30 minutes of the completion of the infusion of the unmanipulated UCB unit, through a central line without in-line filtration in a manner identical to the unmanipulated UCB unit.
On Day 0, the unmanipulated UCB unit will be infused FIRST through a central line without in-line filtration per institutional guidelines.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Number of Patients With the Complement 3a (C3a) Unit Predominating
Prazo: Day 180
Efficacy of the pre-incubation of one of two umbilical cord blood (UCB) units with C3a as part of a unrelated donor double UCB nonmyeloablative transplantation in patients with high-risk hematological malignancies.
Day 180

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Neutrophil Engraftment
Prazo: Day 42
Achieving 500 neutrophils/uL by day 42.
Day 42
Donor Chimerism in Blood
Prazo: Day 28
Percentage of donor DNA present in the peripheral blood
Day 28
Incidence of Grades II-IV Graft-vs-host Disease
Prazo: Day 0 through Day 100
Development of graft-versus-host disease through day 100.
Day 0 through Day 100
Non-Relapse Mortality
Prazo: Day 180
Deaths not due to relapse.
Day 180
Overall Survival
Prazo: Day 360
Survival (alive) from transplantation to last follow-up.
Day 360
Bone Marrow Chimerism
Prazo: Day 21
Percentage of donor DNA in the bone marrow.
Day 21
Chronic Graft-Versus-Host Disease
Prazo: Day 360
Patients who developed chronic graft-versus-host disease.
Day 360
Relapse of Disease
Prazo: Day 360
Patients who developed disease relapse after transplantation.
Day 360
Disease Progression
Prazo: Day 360
Patients who developed disease progression after transplantation.
Day 360
Platelet Recovery
Prazo: Day 180
Number of patients with >20,000 platelets/uL by day 180
Day 180
Donor Chimerism in Blood
Prazo: Day 60
Percentage of donor DNA present in the peripheral blood
Day 60
Incidence of Grades III-IV Graft-vs-host Disease
Prazo: 0 to 100 days
Development of graft-versus-host disease by day 100.
0 to 100 days
Non-relapse Mortality
Prazo: Day 360
Deaths not due to relapse.
Day 360
Overall Survival at Day 720
Prazo: 720 days
Survival (alive) from transplantation to last follow-up at day 720.
720 days
Relapse of Disease
Prazo: Day 720
Patients who developed disease relapse after transplantation.
Day 720
Disease Progression
Prazo: Day 720
Patients who developed disease progression after transplantation.
Day 720
Donor Chimerism
Prazo: Day 100
Percentage of donor DNA in the bone marrow.
Day 100
Donor Chimerism
Prazo: Day 180
Percentage of donor DNA in the bone marrow.
Day 180
Donor Chimerism
Prazo: Day 360
Percentage of donor DNA in the bone marrow.
Day 360

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Claudio G. Brunstein, MD, PhD, Masonic Cancer Center, University of Minnesota

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo

1 de março de 2010

Conclusão Primária (Real)

1 de agosto de 2012

Conclusão do estudo (Real)

1 de agosto de 2013

Datas de inscrição no estudo

Enviado pela primeira vez

21 de agosto de 2009

Enviado pela primeira vez que atendeu aos critérios de CQ

21 de agosto de 2009

Primeira postagem (Estimativa)

24 de agosto de 2009

Atualizações de registro de estudo

Última Atualização Postada (Real)

28 de dezembro de 2017

Última atualização enviada que atendeu aos critérios de controle de qualidade

3 de dezembro de 2017

Última verificação

1 de dezembro de 2017

Mais Informações

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever